Management ChangeMay 6, 2026, 05:17 PM
Trinity Biotech Appoints Jerry Lydon; Reports Q4 2025 Results
AI Summary
Trinity Biotech appointed Jerry Lydon as Head of North America Commercial Operations to strengthen execution and drive profitability, aligning with its Comprehensive Transformation Plan. The company reported Q4 2025 revenues of $11.1 million, a decrease from $15.9 million in Q4 2024, primarily due to disruptions in HIV testing markets and supply chain adjustments. Despite lower sales, gross margin improved by over 400 basis points to 35.2%. For the full year 2025, revenues were $43.8 million, down from $61.6 million in 2024, but gross margin increased to 38.6%.
Key Highlights
- Jerry Lydon appointed Head of North America Commercial Operations.
- Q4 2025 revenue was $11.1 million, down from $15.9 million in Q4 2024.
- Q4 2025 gross margin increased over 400 basis points to 35.2%.
- Q4 2025 net loss was $17.5 million, including a $10.0 million IFRS charge.
- Full year 2025 revenue was $43.8 million, down from $61.6 million in 2024.
- Full year 2025 gross margin increased almost 400 basis points to 38.6%.
- TrinScreen™ HIV manufacturing scaled to targeted levels by early Q2 2026.
- Uni-Gold™ HIV manufacturing commenced scaling in Q2 2026 after regulatory approval.
Price Impact
More from TRIB